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SUMMARY – In this paper, we report our experience from a prospective study in 40 ischemic 
stroke patients admitted during the last two years at University Department of Neurology Stroke 
Unit, Banja Luka Clinical Center, in order to assess the safety and effi  cacy of thrombolytic therapy, 
the impact of age, sex and risk factors, and functional outcome at 6 months of intravenous tissue 
plasminogen activator treatment. According to the National Institutes of Health Stroke Scale, there 
were 5 mild, 22 moderate and 13 severe stroke cases in the study group. Th e outcome measures at 6 
months of thrombolytic treatment were taken in 38 (100%) patients, yielding a Functional Indepen-
dent Measure score 90 (good clinical outcome) in 21 (52.50%) and modifi ed Rankin Score 2 (good 
clinical outcome) in 22 (55%) patients. Th e rate of symptomatic intracerebral hemorrhage in tissue 
plasminogen activator treated patients was 5%, with a mortality rate of 17.50%. Th e outcomes were 
comparable with those found in the NINDS t-PA trial. Current guidelines recommend a ‘door-to-
needle’ time of less than 60 minutes and emphasize that ‘time is brain’.
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Introduction
Th e ‘time is brain’ concept means that treatment of 
stroke should be considered as an emergency. In 1996, 
the Food and Drug Administration approved intrave-
nous tissue plasminogen activator (tPA) for the treat-
ment of acute ischemic stroke within 3 hours of onset. 
Th is approval was granted thanks to the favorable re-
sults obtained in the pivotal National Institutes of Neu-
rological Disorders and Stroke (NINDS) tPA trial1. 
Stroke is sudden death of brain cells in a local-
ized area due to inadequate blood fl ow, which is the 
result of thrombosis, embolism or hemorrhage, and 
one of the three most common and serious diseases 
with high medical, emotional and socioeconomic 
consequences to the elderly, their families and health 
care system. It is estimated that in 2002, the number 
of deaths due to stroke reached 5.51 million world-
wide, with two-thirds of these deaths occurring in 
developing countries2. It is also a major cause of long-
term disability3, and the second most common cause 
of death, the fi rst being heart attacks and the third 
cancer, with a tendency to become the leading cause 
of death worldwide4.
Based on recent defi nitions of transient ischemic 
attack (TIA), both ischemic stroke and TIA, which 
are now considered to be a single entity, are defi ned as 
infarction of the central nervous system (CNS) tissue. 
Unlike TIA, ischemic strokes may be symptomatic 
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or silent, i.e. asymptomatic. Symptomatic ischemic 
strokes are manifested by clinical signs of focal or 
global cerebral, spinal or retinal dysfunction caused 
by CNS infarction5.
Within the areas of severely reduced blood fl ow, 
the ‘core’ of ischemic territory, excitotoxic and necrotic 
cell death occurs within minutes, and tissue undergoes 
irreversible damage in the absence of prompt and ad-
equate reperfusion. However, cells in peripheral zones 
are supported by collateral circulation, and their fate is 
determined by several factors including the degree of 
ischemia and timing of reperfusion. In this peripheral 
region termed ‘ischemic penumbra’, cell death occurs 
relatively slowly via the active cell death mechanisms. 
Targeting these mechanisms provides therapeutic op-
portunities6. 
Th e goal of thrombolytic therapy is to restore brain 
blood fl ow in ischemic stroke. Th is is accomplished by 
clot lysis that results in reperfusion of aff ected but not 
yet infarcted tissue. Th e greatest risk of thrombolytic 
therapy is symptomatic intracerebral hemorrhage. Al-
though the risk of hemorrhage increases with throm-
bolytic therapy, the risk is outweighed by improved 
functional outcome at 3 months of stroke onset. 
Randomized controlled trial sponsored by the Na-
tional Institute of Neurological Disorders and Stroke 
(NINDS) supported the view that tPA should be part 
of the management of acute ischemic stroke within 
three hours of onset in selected patients in experi-
enced centers1. However, there is no full agreement. 
A study of tPA use in smaller community hospitals 
found a high rate of symptomatic intracerebral hem-
orrhage (15.7%), with 50% of patients treated without 
observing the NINDS guidelines7. Nevertheless, only 
1% to 6% of all patients admitted for ischemic stroke 
receive a thrombolytic agent8,9.
We report our experience with thrombolysis for 
stroke between April 2007 and April 2009.
Patients and Methods
Th is was a prospective study to assess the safety 
and effi  cacy of thrombolytic therapy, the impact of 
age, sex and risk factors, and functional outcome at 
six months. Th e patients were clinically assessed us-
ing the National Institutes of Health Stroke Scale 
(NIHSS) at the baseline, just before the adminis-
tration of tPA, and at discharge from the hospital. 
Th e protocol was not formally approved by the Eth-
ics Board of the Banja Luka Clinical Center because 
the study only observed outcomes after the standard 
treatment intervention. Data were collected prospec-
tively by the Stroke Care Unit authorized personnel. 
We recorded baseline data, including patient demo-
graphic characteristics, time from symptom onset to 
arrival to the neurology department, time to tPA ad-
ministration, NIHSS (on admission, atrial fi brillation 
past or current), pretreatment of blood pressure, full 
blood testing, serum glucose levels, length of hospital 
stay, and NIHSS score at discharge. All patients un-
derwent follow up computed tomography (CT) imag-
ing at 24 h or when clinically indicated. Intracerebral 
hemorrhage was considered symptomatic when it led 
to a 4-point or greater increase in the NIHSS score. 
Th e patients were followed up for six months. Th ey 
were assigned a score on the modifi ed Rankin Scale 
(mRS) and Functional Independent Measure (FIM) 
at six months of stroke. 
Treatment protocol
All patients admitted to the hospital within three 
hours of symptom onset were immediately assessed by 
the competent stroke unit staff  comprising of a stroke 
neurologist and trained nurse. Th e tPA protocol and 
inclusion and exclusion criteria were based on the pro-
tocols published by the American Heart Association 
and American Academy of Neurology9,10. Th e patients 
underwent pretreatment CT scans that were assessed 
by the attending neurologist and a radiologist. An in-
formed consent was obtained after discussion of the 
potential benefi ts and signifi cant risks.                                                    
Modifi ed Rankin Scale is a simplifi ed overall 
functional assessment in which score 0 indicates the 
absence of symptoms and score 5 severe disability11. 
Th e Functional Independence Measure is a widely ac-
cepted scale used to assess the functional abilities of 
patients undergoing rehabilitation. Th e outcome was 
assessed by the local rehabilitation team at Dr Miro-
slav Zotović Institute of Physical Medicine and Re-
habilitation, Banja Luka, six months after treatment. 
We obtained clinical or telephone follow up with the 
patient or caregiver in all 38 cases and assessed the 
FIM score Activities of Daily Living Index and modi-
fi ed Rankin Disability Scale (mRS). 
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Telephone interview for assessing stroke outcome 
has been previously validated12. Th e inquiry was made 
regarding the number of weeks spent in the acute 
inpatient rehabilitation, outpatient rehabilitation, 
skilled nursing facilities, nursing homes, and profes-
sional home care. Good clinical outcome was defi ned 
as FIM values of 90/126 and mRS 0/1/213,14.
Results
Demographics
Forty patients were treated with intravenous tPA 
at Banja Luka Clinical Center between April 2007 
and March 2009. During this period, around 1000 
ischemic stroke patients were treated at Stroke Unit. 
Of these 1000 patients, 40 (4%) were treated with 
tPA. Most patients (60%) treated with tPA were male 
(≥13). Th ere were 5 mild, 22 moderate and 13 severe 
strokes in this group. Pertinent medical history re-
vealed that 82.50% had a history of hypertension, 22% 
had diabetes and 30% had a history of atrial fi brilla-
tion (Fig. 1).
According to the Oxfordshire Community Stroke 
Project classifi cation of ischemic stroke (OCSP clas-
sifi cation), 12.5% were posterior circulation syndrome 
(POCS), 30% lacunar circulation syndrome (LACS), 




Age, y mean±SD 61.1±9.1
Sex, male (%) 60 (24)
Onset- needle time 122.6±37.8
Door- needle time 49.1±16.8 
NIHSS (on admission) mean±SD 11.6±4.2




Smoker, n (%) 22 (55)
Diabetes mellitus, n (%) 9 (22.5)
Hypertension (current), n (%) 33 (82.5)
Hyperlipidemia (current), n (%) 25 (62.5)
Atrial fi brillation (past or current) 12 (30)
Length of stay, d±SD 10.6 ±5.0
NIHSS score on discharge, mean±SD 5.22±6.5
Abbrevations: SD: standard deviation, n:  number, PACS: partial 
anterior circulation stroke, TACS: total anterior circulation stroke, 
POCS: posterior circulation stroke, LACS: lacunar stroke
Table 1. Demographic and baseline characteristics of patients 
in the study
(n=24), and mean age was 61±9.1 (mean±SD; range, 
35-74) years (Table 1). 
We stratifi ed the severity of strokes according to 
NIHSS into mild (0-6), moderate (7-12), and severe 
Fig. 1. Distribution of risk factors
42% partial anterior circulation syndrome (PACS) 
(Fig. 2).
We tested the hypothesis that the mean age was 
the same in both groups, survivors and dead, provided 
that there was no statistically signifi cant diff erence 
with the reliability of 95%. However, P value was rela-
tively small (0.0706) and less than 0.1, meaning that 
with the reliability of 90% the mean age was statisti-
Fig. 2. OCSP classifi cation and outcome of thrombolytic 
therapy
cally signifi cant higher in the group of dead than in 
the group of survivors (Fig. 3).
Th e maximum glucose levels ranged from 4.1 to 
13.3 mmol/L, with a median of 6.9 mmol/L. Th ere 
were no statistically signifi cant diff erences when the 
maximum glucose levels were compared among pa-
tients stratifi ed by admission stroke severity: 6.7±1.4 
mmol/L in mild strokes, 7.3±2.3 mmol/L in moder-
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ate strokes, and 7.6±2.1 mmol/L in severe strokes. 
Similarly, comparison of maximum glucose levels be-
tween patients that died and survivors at 6 months 
yielded no statistically signifi cant diff erences either. 
Th e median cholesterol level was 5.83 mmol/L (range 
3.3-9.61) and median triglyceride level 2.07 (range 
0.49-6.06).
Hemorrhage occurred in 15 (37.5%) patients. 
Hemorrhage classifi ed as petechial occurred in 10 
(25%) and hematomatous in 12 (30%) patients. Major 
symptomatic intracranial hemorrhage occurred in two 
(5%) patients (NIHSS score at admission was 12).
Th e mean NIHSS score on admission was 11.6 
(range 5 to 20) (Table 1). Th e median onset-to-treat-
ment time was 122.6 min, SD 37.8 (IQR 45-195 min) 
and median door-treatment time 49.1±16.8 min; 20% 
of patients were treated with tPA within 90 minutes of 
the onset of stroke symptoms and two (5%) were given 
tPA after the recommended time of 180 minutes (190 
and 195 min) (Fig 4). 
Th e mean length of hospital stay was 10.6 (range 1 
to?) days. Twenty-two (55%) patients were discharged 
for home care, ten (25%) to inpatient rehabilitation 
services, and fi ve (12.5%) to nursing homes. Two (5%) 
patients died. Symptomatic intracranial hemorrhage 
occurred in two (5%) patients. At discharge, 45% of 
tPA treated patients had NIHSS score 0 or 1, while 
70% had more than 4-point improvement on NIHSS 
as compared with admission scores. Th e mean dis-
charge NIHSS score was 5.22 (range, 0-20) (Fig 5).
Survival could be evaluated in 38 (100%) patients; 
fi ve of 38 (13.15%) patients died in the fi rst six months. 
During the 6-month study period, the mortality rate 
was 17.5% (Table 2). Statistically signifi cant diff er-
ences were observed when NIHSS score at admission 
in patients that died was compared with 6-month sur-
vivors (ANOVA, F-ratio 9.71181; P<0.05; 95% confi -
dence level).
At six months, FIM and mRS were performed in 
38 (100%) patients. Scores 0, 1 and 2 on mRS, indicat-
ing no symptoms or minimal handicap, were recorded 
in 22 (55%) patients, FIM score 90/126 in 21 (52.5%) 
patients (Table 2).
Table 2. Outcome measures after 6 months
Outcome measure after six months  % n(40)
% FIM score ≥90 (good clinical outcome) 52.5 21 
% Modifi ed Rankin Score <2
(good clinical outcome)
55 22
Mortality rate 17.5 7
Fig. 3. Infl uence of age on the outcome of thrombolytic 
therapy
Fig. 4. Distribution of time from the onset of symptoms to 
the time of thrombolysis
Fig. 5. NIHSS on admission and discharge.
Discussion
Study results showed the intravenous tPA therapy 
to be benefi cial in ischemic stroke, when treatment 
was initiated within three hours of symptom onset. 
Outcomes were comparable to those found in the 
NINDS trial. One half of our tPA treated patients 
were functionally independent at follow up (mRS 
0-2), compared with 49% of those in the NINDS 
trial. Th e rate of symptomatic intracerebral hemor-
rhage in our tPA-treated patients was 5%, similar to 
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that observed in the NINDS trial (6.4%). Th e mortal-
ity rate was quite comparable to the NINDS trial too 
(17.5% vs. 17%)15,16. Current guidelines recommend a 
door-to-needle time of less than 60 minutes and em-
phasize that ‘time is brain’17. Our door-to-needle time 
median was 49 minutes. Of 40 patients, two were 
treated beyond the 180-min window, i.e. at 190 and 
195 min, with no major complications. Of importance 
is also the degree of clinical improvement. Th e mRS 
and FIM score represent the entire range of function, 
from death and severe disability to complete recov-
ery. Th e NIHSS assesses neurological defi cit and not 
functional outcome. Complete recovery also means 
complete neurological recovery regardless of function. 
Higher NIHSS score, longer time to recanalization 
and elevated glucose proved to be important predic-
tors of hemorrhage17. Further organization of stroke 
centers is required to address this inequity of access to 
thrombolytic treatment. 
Intravenous thrombolysis represents the most ef-
fective acute stroke therapy. However, it is almost ex-
clusively performed in stroke centers and is not avail-
able in wider community areas. Th e main rate-limiting 
step in provision of thrombolytic therapy is the three-
hour time window. Th e possibility to administer this 
therapy outside the hospital is required before throm-
bolytic therapy for stroke is more widely applied. In 
areas where emergency services treat stroke with the 
same priority as acute myocardial infarction, admis-
sion to hospital is more rapid18. 
Although the success of acute thrombolytic thera-
py in urban hospitals is confi rmed where neurologists 
are readily available, questions still arise as to the ap-
plicability and safety of tPA administration for acute 
ischemic stroke in the community and rural hospitals. 
Our center is recognized as a specialized Stroke Unit, 
with a dedicated and trained team available 24 hours 
a day. A low number of the treated compared to the 
total number of strokes suggests insuffi  ciently devel-
oped infrastructure to support emergency arrival to 
the Stroke Unit. Our next challenge is to increase the 
percentage of patients that can be provided tPA thera-
py. Up to 10% of patients with stroke can be appropri-
ately treated with tPA in well organized centers11.
Th e recently published European Cooperative 
Acute Stroke Study III (ECASS III) has shown that 
intravenous alteplase administered between 3 and 4.5 
hours (median 3 h 59 min) after the onset of symptoms 
signifi cantly improves clinical outcomes in patients 
with acute ischemic stroke compared to placebo; the 
absolute improvement was 7.2% and the adjusted OR 
of favorable outcome (mRS 0-1) was 1.42, 1.02-1.98. 
Mortality did not diff er signifi cantly (7.7% vs. 8.4%), 
but alteplase increased the risk of symptomatic intrac-
erebral hemorrhage (2.4% vs. 0.2%). Treatment ben-
efi t is time-dependent. Th e number needed to treat to 
get one more favorable outcome drops from two dur-
ing the fi rst 90 minutes through seven within 3 hours, 
and towards 14 between 3 and 4.5 hours19.
Th e SITS investigators compared 664 patients 
with ischemic stroke treated between 3 and 4.5 hours 
otherwise compliant with the European summary of 
the product characteristics criteria with 11 865 pa-
tients treated within 3 hours20.
In the 3- to 4.5-hour cohort, treatment was start-
ed on average 55 minutes later after symptom onset. 
Th ere were no signifi cant diff erences between the 
3- to 4.5-hour cohort and the 3-hour cohort for any 
outcome measures, confi rming that alteplase remains 
safe when given between 3 and 4.5 hours after the 
onset of symptoms in ischemic stroke patients that 
otherwise fulfi ll the European summary of product 
characteristics criteria21.
Actually, thrombolysis treatment is recommended 
to administer within 4.5 hours of the onset of ischemic 
stroke (Class I, Level A). Our study was performed be-
fore changes of these recommendations in the Euro-
pean labeling, implemented as of January 29, 200922. 
Conclusion
Th is prospective study included 40 ischemic stroke 
patients admitted during the last two years (April 
2007 – March 2009) to the University Department of 
Neurology Stroke Unit, Banja Luka Clinical Center. 
Th e aim of the study was to assess the safety and ef-
fi cacy of thrombolytic therapy, the impact of age, sex 
and risk factors, and six-month functional outcome 
with intravenous tPA therapy. Study results proved 
the benefi t of intravenous tPA therapy when treat-
ment was initiated within 3 hours of symptom onset. 
Our door-to-needle median time was 49 minutes. Of 
40 patients, two were treated beyond the 180-minute 
window, i.e. at 190 and 195 minutes, with no signifi -
cant complications.
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Most patients (60%) treated with tPA were male 
(n=24), mean age 61±9.1 years; 82.5% had a history of 
hypertension, 22% had diabetes and 30% had a his-
tory of atrial fi brillation. According to NIHSS, the 
severity of stroke ranged from mild in fi ve, moderate 
in 22 and severe in 13 patients.
Outcomes were comparable with those found by 
the NINDS trial; 52.5% of our tPA treated patients 
were functionally independent at follow up (mRS 
0-2), compared with 49% in the NINDS trial.
Th e rate of symptomatic intracerebral hemorrhage 
in our tPA-treated patients was 5%, very similar to 
6.4%, and the mortality rate was similar to that ob-
served in the NINDS trial (17.5% vs. 17%). Th e mean 
age in the group of dead was statistically signifi cantly 
higher than in the group of survivors. Of importance 
is also the degree of clinical improvement. Th e mRS 
and FIM score represent the entire range of functions, 
from death and severe disability to complete recovery. 
Th e NIHSS assesses neurologic defi cit and not func-
tional outcome. Complete recovery also means com-
plete neurologic recovery regardless of function. 
Higher NIHSS score, longer time to recanaliza-
tion and elevated glucose proved important predictors 
of hemorrhage. Further organization of stroke centers 
is required to address this inequity of access to throm-
bolytic treatment.
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Sažetak
FUNKCIONALNI ISHOD NAKON LIJEČENJA TROMBOLIZOM
S. Miljković, D. Prtina, T. Rabi Žikić, Z. Vujković, D. Račić, V. Đajić, A. Ješić, M. Arbutina i M. Žikić 
U radu iznosimo naša iskustva iz prospektivne studije kod 40 pacijenata sa ishemičnim moždanim udarom, liječenih 
u Jedinici za moždani udar Klinike za neurologiju Kliničkog Centra Banja Luka tokom posljednje dvije godine, da bi 
se procijenila pouzdanost i efi kasnost trombolitičke terapije šest mjeseci nakon intravenske primjene aktivatora tkivnog 
plazminogena, kao i uticaj životne dobi, spola i faktora rizika na funkcionalni ishod nakon moždanog udara. Među njima 
je, prema skali za moždani udar Nacionalnog instituta za zdravlje SAD, bilo pet blagih, 22 umjerena i 13 teških oblika 
moždanog udara. Efi kasnost terapije nakon šest mjeseci od trombolize kod 38 preživjelih pacijenata prezentirana je zbirom 
Nezavisnog funkcionalnog mjerenja 90 (dobar klinički ishod) kod 21 (52,50%) pacijenta, te kao modifi cirani Rankinov 
zbir 2 (dobar klinički ishod) kod 22 (55%) pacijenta. Učestalost intrakranijalne hemoragije bila je 5%, sa stopom smrtnosti 
od 17,50%. Rezultati funkcionalnog ishoda su uspoređeni sa ishodom navedenim u studiji NINDS t-PA. Važeće preporu-
ke savjetuju da vrijeme od “vrata do igle” bude kraće od 60 minuta, naglašavajući izreku “vrijeme je mozak”.
Ključne riječi: Moždana ishemija – dijagnostika; Moždana ishemija – terapija lijekovima; Moždani udar – dijagnostika; 
Moždani udar – terapija lijekovima; Fibrinolitički lijekovi – terapijska primjena; Trombolitička terapija – vremenski čimbenici
22. Guidelines for management of ischaemic stroke and transient 
ischaemic attack 2008. Th e European Stroke Organization 
(ESO) Executive Committee and the ESO Writing Com-
mittee. Version: 16.03.2008 (modifi ed January 2009).
